Nautilus Biotechnology (NASDAQ:NAUT) Issues Quarterly Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) posted its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.21 million.

Here are the key takeaways from Nautilus Biotechnology’s conference call:

• Voyager development remains on track, with pre-orders expected in early 2027 and instrument shipments, along with tau, AKT1, and another oncology assay, targeted for mid-2027.
• Early oncology assays showed strong reproducibility, with median coefficient of variation of 8.8% for AKT1, 3.6% for EGFR, and 6.6% for P53—below the company’s 10% target. Nautilus is targeting 20 proteoform assays by mid-2028 and expects to reduce sample-input requirements by roughly 100-fold before general availability.
• Nautilus secured participation in the ARPA-H-backed SEEDS Consortium, potentially providing up to $6 million over four years for tau and EWS-FLI1 work, including tissue and biofluid studies and platform development. Management also cited growing interest from academic, nonprofit, and pharmaceutical customers.
• Third-quarter revenue was only $0.2 million, generated from grant funding and early-access services, although management expects fourth-quarter revenue to increase sequentially and full-year 2026 revenue to exceed its prior outlook of approximately $0.5 million.
• The company used approximately $14.9 million of cash during the quarter and ended Q3 with $114.3 million in cash and investments, supporting a runway into Q1 2028. Management is exploring a potential capital raise before mid-2027 to fund assay expansion, platform development, and commercial hiring, which could dilute shareholders.

Nautilus Biotechnology Stock Up 0.5%

NAUT traded up $0.01 during trading hours on Thursday, hitting $3.23. The stock had a trading volume of 4,085,851 shares, compared to its average volume of 1,930,673. The company’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $2.10. Nautilus Biotechnology has a 1 year low of $0.84 and a 1 year high of $4.31. The stock has a market cap of $410.40 million, a PE ratio of -7.17 and a beta of 0.73.

Analysts Set New Price Targets

A number of equities research analysts recently commented on NAUT shares. Roth Capital initiated coverage on Nautilus Biotechnology in a research report on Tuesday, September 29th. They issued a “buy” rating and a $3.50 price target for the company. Zacks Research upgraded shares of Nautilus Biotechnology to a “hold” rating in a research note on Wednesday, September 30th. Leerink Partners started coverage on shares of Nautilus Biotechnology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target for the company. Finally, Weiss Ratings upgraded shares of Nautilus Biotechnology from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $3.83.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.